$AZN Enhertu cancer drug has been added to China's health insurance scheme, expanding access to innovative cancer treatments for patients: https://ibn.fm/erFbf #AstraZeneca #Enhertu #Healthcare #CancerTreatment #China
BioMedWire
在线音视频媒体
San Francisco，California 3,739 位关注者
Keeping the public abreast of the latest developments related to emerging market opportunities in the sector.
关于我们
A specialized communications platform, a digital hub that aggregates and distributes news and information on the latest developments in the life sciences sector. Designed to quickly update investors on important industry news, BioMedWire is committed to keeping the public abreast of the latest developments related to emerging market opportunities in the sector. We cover companies and events in the fields of biotechnology, pharmaceuticals, life systems technologies, environmental, nutraceuticals, cosmeceuticals, medical, biomedical devices and more. We delve into people, companies and institutions that are devoted to the research and development of the next cancer therapeutic, critical device or lifesaving vaccine. BioMedWire has established a reputation as the go to source for its coverage of sector events that have market moving impact. Some of the greatest market returns have been delivered by the life sciences which has provided cures and remedies for the masses and massive rewards for investors. As a champion of the life sciences, BMW is committed to connecting the investing public to the intelligence used to identify the sector’s next great success story. The life sciences, pharmaceutical and biotech industries are massive and move quickly, BMW strives to provide the most comprehensive industry news and information to keep followers and investors up to date on important developments. From mergers to drug and device approvals, the business is constantly changing, and we’ll do our best to keep you abreast of what matters. BioMedWire provides insights into the most impactful news and trends shaping the life sciences sector and beyond. We endeavor to shed new light on companies in the sector with breakout potential, ready to market a new therapy or device, on their way to becoming industry heavyweights. Follow us to find the insights and the opportunities in the sector that has the greatest impact on humanity's well-being. Disclaimer: https://ibn.fm/bmw
- 网站
-
https://www.biomedwire.com
BioMedWire的外部链接
- 所属行业
- 在线音视频媒体
- 规模
- 1 人
- 总部
- San Francisco，California
- 类型
- 私人持股
地点
-
主要
获取路线
US，California，San Francisco
BioMedWire员工
动态
-
$AZN secures CDSCO approval to import an advanced anti-cancer drug. A step forward in providing innovative treatments for patients in need: https://ibn.fm/x5ZuM #AstraZeneca #CancerResearch #PharmaInnovation #Healthcare #MedicalAdvances
AstraZeneca Pharma Gets CSDCO Nod To Import Anti-Cancer Drug
bizzbuzz.news
-
$MRK and Kelun's ADC earns its first nod, targeting Trop2 in the fight against cancer. A major step forward in oncology treatment: https://ibn.fm/tCqlv #Merck #Oncology #Trop2 #PharmaInnovation #ADC
-
$LLY faces competition as Amgen enters the obesity drug market with maritide, targeting GLP-1 and GIP receptors. Could this reshape weight loss treatments?: https://ibn.fm/kyf0j #EliLilly #Amgen #Obesity #PharmaInnovation #WeightLoss
Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator - MedCity News
https://medcitynews.com
-
BioMedNewsBreaks — $SCNI Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board https://ibn.fm/0xEBE
-
-
$MRK WINREVAIR meets the primary endpoint in the Phase 3 ZENITH study, advancing treatment options for patients with chronic obstructive pulmonary disease: https://ibn.fm/Pk7eT #Merck #COPD #WINREVAIR #Phase3 #Pharmaceuticals
Merck's Winrevair meets primary endpoint in Phase 3 ZENITH study
worldpharmaceuticals.net
-
BioMedNewsBreaks – $MODD Announces Pricing of $8.2M Public Offering https://ibn.fm/tUbxf
-
-
BioMedNewsBreaks – $KAPA Engages IBN for Corporate Communications Expertise https://ibn.fm/Bej8c
-
-
$AZN TRuQAP combo treatment for prostate cancer has shown promising results in clinical trials. The combination therapy could potentially offer a significant advancement in treatment options for patients: https://ibn.fm/jcxAf #AstraZeneca #TRuQAP #CancerTreatment #Oncology
AstraZeneca reports results from trial of combination therapy for prostate cancer
clinicaltrialsarena.com
-
MS Drug Could Counter Poor Working Memory $CLNN https://ibn.fm/HtCP2 #biomedstocks #Memory
-